Silencing GNAS enhances HDAC3i efficacy in CREBBP wild type B cell lymphoma.
| Autor: | Mondello P; Division of Hematology, Mayo Clinic, Rochester, MN, USA. mondello.patrizia@mayo.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Leukemia [Leukemia] 2024 Oct; Vol. 38 (10), pp. 2087-2089. Date of Electronic Publication: 2024 Jul 19. |
| DOI: | 10.1038/s41375-024-02355-y |
| Abstrakt: | The genetic era has opened the opportunity of using personalized therapeutic approaches, in part based on targeting genes with somatic mutations. For example, lymphomas harboring the highly recurrent CREBBP mutation show dependency on HDAC3, thus selective inhibition of HDAC3 reversed the epigenetic effects of CREBBP mutation, halted lymphoma growth, and induced MHC class II expression, enabling the T-cells to recognize and kill lymphoma cells. However, CREBBP wild type (WT) cells are less sensitive to this approach. In this issue of Leukemia, He et al. have executed a genome-wide CRISPR screening that identified GNAS as a target to maximize the therapeutic activity of HDAC3 inhibition in CREBBP WT lymphoma. (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink